Clinical Trials Logo

Gout Flare clinical trials

View clinical trials related to Gout Flare.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05936268 Recruiting - Gout Flare Clinical Trials

Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare

Gensci 048-203
Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Genakumab for Injection in patients with gout flare as a first line therapy

NCT ID: NCT05658575 Recruiting - Arthritis Clinical Trials

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Start date: January 6, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.

NCT ID: NCT05586971 Recruiting - Gout Clinical Trials

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

EURELIA2
Start date: March 30, 2023
Phase: Phase 3
Study type: Interventional

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.

NCT ID: NCT05586958 Recruiting - Gout Clinical Trials

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

EURELIA1
Start date: October 25, 2022
Phase: Phase 3
Study type: Interventional

The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.

NCT ID: NCT05522504 Recruiting - Gout Flare Clinical Trials

Distribution of Immune Cells and Their Subtypes in Peripheral Blood of Gout

Start date: September 15, 2021
Phase:
Study type: Observational

The purpose of this study is to evaluate whether immune cells and their subtypes in peripheral blood affects the asymptomatic hyperuricemia, gout flare, intercritical gout and advanced gout.

NCT ID: NCT03933007 Recruiting - Gout Flare Clinical Trials

Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare

COMpARE
Start date: September 10, 2019
Phase: Phase 4
Study type: Interventional

Gout, secondary to sodium urate crystal deposition, is responsible of recurrent inflammatory painful flares. Efficacy of colchicine which is the first line drug for the treatment and prophylaxis of gout flare varies and only half of treated patients experience good response. This study aims to optimize colchicine prescription for the treatment and prophylaxis of gout flare. Current data suggest that efficiency of colchicine relies on its maximum blood concentration (Cmax). In this study, the investigators hypothesize that responders to colchicine treatment have higher colchicine Cmax than non-responder patients following the recommended dose regimen (1 mg then 0.5 mg 1 hour later). The individual pharmacokinetics (PK) of colchicine remains poorly investigated while the assessment of individual drug metabolisms can be performed. The hypothesis of this study stands that several factors contribute to the variability of colchicine Cmax. The analysis of individual PK profile and a well-characterized metabolism of colchicine will permit a personalized treatment regimen for the treatment and prophylaxis of gout flares.

NCT ID: NCT03524222 Recruiting - Asthma Clinical Trials

Home Hospital for Suddenly Ill Adults

Start date: January 18, 2018
Phase: N/A
Study type: Interventional

The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be delivered in the home with equal quality and safety, reduced cost, and improved patient experience.